Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Immunologic activity of an activating anti-CD27 antibody (CDX-1127) in patients (pts) with solid tumors.
Infante, Jeffrey R., Burris, Howard A. , Ansell, Stephen M. , Villalobos, Víctor M. , Šikić, Branimir I. , Northfelt, Donald W. , Pilja, Lana, Hawthorne, Thomas, Davis, Thomas A. , Keler, Tibor , Nemunaitis, John , Weiss, Geoffrey R. , Taylor, Matthew H. , Carson, William E. , Yellin, Michael , Bullock, Timothy N J

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3027-3027

10.1200/jco.2014.32.15_suppl.3027 Get It

Phase I evaluation of an agonist anti-CD27 human antibody (CDX-1127) in patients with advanced hematologic malignancies.
Ansell, Stephen M. , Northfelt, Donald W. , Burris, Howard A. , Dinner, Shira, Villalobos, Víctor M. , Šikić, Branimir I. , Pilja, Lana, Hawthorne, Thomas, Keler, Tibor , Davis, Thomas A., Flinn, Ian W. , Taylor, Matthew H. , Yellin, Michael , Davis, Thomas A.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 3024-3024

10.1200/jco.2014.32.15_suppl.3024 Get It

Vismodegib in the treatment of patients with metastatic basal cell carcinoma (mBCC) and distant metastases: Survival in the pivotal phase II and phase I studies.
Lewis, Karl D. , Sekulić, Aleksandar , Migden, Michael R. , Oro, Anthony E. , LoRusso, Patricia , Hainsworth, John D. , Williams, Sarah, Hou, Jeannie , Hoff, Daniel D. Von , Hauschild, Axel , Rudin, Charles M. , Dirix, Luc , Solomon, James A.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 9012-9012

10.1200/jco.2014.32.15_suppl.9012 Get It

Identification of independent primary tumors and intra-pulmonary metastasis using DNA rearrangements in non-small cell lung cancer.
Aubry, Marie‐Christine, Harris, Faye R. , Johnson, Sarah H. , Terra, Simone Barreto Siqueira Parrilha, Peikert, T., Yi, Eunhee S. , Vasmatzis, George , Wigle, Dennis A. , Murphy, Stephen J. , Aubry, Marie-Christine, Asiedu, Michael K. , Yang, Ping

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: e18515-e18515

10.1200/jco.2014.32.15_suppl.e18515 Get It

Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial.
Yoon, Harry H. , Bendell, Johanna C. , Braiteh, Fadi S., Firdaus, Irfan , Philip, Philip Agop, Cohn, Allen Lee, Lewis, Nancy , Anderson, D. Mark , Arrowsmith, Edward, Schwartz, Jonathan D. , Xu, Yihuan, Koshiji, Minori, Anderson, Daniel M., Alberts, Steven R. , Wainberg, Zev A.

Mayo Clinic

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: 4004-4004

10.1200/jco.2014.32.15_suppl.4004 Get It

Determining the utility of standard hospital microbiology testing: Comparing standard microbiology cultures with DNA sequence analysis in patients with chronic sinusitis
Rapoport, Sarah K. , Smith, Alyssa J. , Bergman, Maxwell , Scriven, Kelly A., Mikula, Suzette, Brook, Itzhak

Mayo Clinic

World Journal of Otorhinolaryngology - Head and Neck Surgery | January 3, 2019 | Volume: 5 | Issue: 2 | Pages: 82-87

10.1016/j.wjorl.2018.11.001 | PMID 31334486 Get It

Objective To demonstrate DNA sequencing analysis (DNAsa) of sinus cultures in patients with CRS is a reliable method of detecting pathogens in polymicrobial CRS infections. Methods After obtaining Institutional Review Board approval for this prospective cohort study, we selected a random sample of 50 patients with CRS at Medstar Georgetown University Hospital between September 2016 and March 2017. We defined CRS as a history of rhinosinusitis refractory to maximal medical therapy and prior endoscopic sinus surgery. Patients demonstrating active purulence in a sinus cavity were prospectively selected to undergo standard hospital cultures (SHC) and DNAsa cultures. Organisms identified in both methods were compared for each patient. Results Specimens were obtained from 29 female and 16 male patients with a mean age of 50 years. A total of 45 cultures were included in our final analysis; five cultures were excluded after inappropriate laboratory processing. Results from these patients were compared and analyzed. Cohen's weighted kappa analysis showed agreement between the two testing methods in identifying predominant microorganisms. DNAsa detected 31.9% more microorganisms compared to SHC ( P < 0.05). When multiple microorganisms were detected, DNAsa yielded more positive results compared to SHC ( P < 0.05). Conclusions DNAsa detects all microorganisms identified by SHC as well as predominant microorganisms not detected by SHC. Thus molecular pathogen identification may be more reliable for identifying multiple microorganisms as compared to standard culture techniques that identify only one or two microorganisms. In recalcitrant cases of CRS, DNAsa may provide better guidance in selection of appropriate antimicrobial treatment.
ClarIDHy: A phase 3 multicenter randomized double-blind study of AG-120 versus placebo in patients with non-resectable or metastatic cholangiocarcinoma with an IDH1 mutation.
Kelley, Robin Kate , Shroff, Rachna T. , Javle, Milind , Cleary, James M. , Bendell, Johanna C. , Vogel, Arndt , Korth, C, Jiang, Liewen, Gliser, Camelia, Wu, Bin , Agresta, Samuel , Pandya, Shuchi S., Zhu, Andrew X. , Abou‐Alfa, Ghassan K. , Valle, Juan W. , Goyal, Lipika , Borad, Mitesh J. , El-Khoueiry, Anthony B. , Macarulla, Teresa , Vogel, Arndt , Korth, Christopher

Mayo Clinic

Journal of Clinical Oncology | January 2, 2019 | Volume: 36 | Issue: 4_suppl | Pages: TPS545-TPS545

10.1200/jco.2018.36.4_suppl.tps545 Get It

TPS545 Background: Advanced cholangiocarcinoma (CC) is a life-threatening disease with limited effective chemotherapy options. Mutations in isocitrate dehydrogenase 1 (mIDH1) occur in 13–15% of CC cases, and up to 25% of intrahepatic CC cases, leading to epigenetic and genetic changes that promote oncogenesis via production of the oncometabolite 2-hydroxyglutarate (2-HG). AG-120 (ivosidenib), a first-in-class oral mIDH1 inhibitor, displayed a favorable safety profile and clinical activity in a phase 1 study enrolling 73 mIDH1 CC patients who had received ≥1 prior systemic regimen. As of 10 Mar 2017, 4/73 (5%) had a partial response and 41/73 (56%) stable disease. Progression free survival (PFS) rates at 6 months and 12 months were 38.5% and 20.7%, respectively. The 500 mg once daily dose level of AG-120 was selected for further development in mIDH1 CC. Methods: ClarIDHy is a global, phase 3, multicenter, double-blind, randomized (2:1) study of AG-120 (500 mg once daily) vs. matched placebo in 186 mIDH1 CC patients (ClinicalTrials.gov NCT02989857). Key eligibility criteria: non-resectable or metastatic CC, documented mIDH1 by central laboratory testing, ECOG performance status 0–1, measurable disease (RECIST v1.1), documented disease progression after ≤2 prior systemic therapies in the advanced setting including at least 1 gemcitabine- or 5-fluorouracil-containing regimen, and no prior mIDH inhibitor therapy. Crossover from placebo to AG-120 will be allowed at time of radiographic disease progression. Primary endpoint: PFS assessed by independent radiologists. Secondary endpoints: safety, tolerability, overall response rate (RECIST 1.1), overall survival, pharmacokinetic/pharmacodynamic analyses, and quality of life (EORTC QLQ-C30 and QLQ-BIL21 scales). An independent data monitoring committee will monitor the data during study conduct. The ClarIDHy study is currently activated at participating sites in the US, UK, EU, and S. Korea. R eused with permission from the American Society of Clinical Oncology (ASCO). This abstract was accepted and previously presented at the 2017 ASCO Annual Meeting. All rights reserved. Clinical trial information: NCT02989857.
Heterogeneity of risk within Gleason 4 + 4, 4 + 5 and 5 + 4 prostate cancer
Moschini, Marco , Sharma, Vidit , Soligo, Matteo, Rangel, Laureano J. , Boorjian, Stephen A. , Frank, Igor, Gettman, Matthew T., Thompson, R. Houston, Tollefson, Matthew K. , Karnes, R. Jeffrey , Psutka, Sarah, Rangel, Laureano, Moschini, Marco , Psutka, Sarah P.

Mayo Clinic

Scandinavian Journal of Urology | January 2, 2019 | Volume: 52 | Issue: 5-6 | Pages: 340-348

10.1080/21681805.2018.1534886 | PMID 30600747 Get It

Should pretest genetic counselling be required for patients pursuing genomic sequencing? Results from a survey of participants in a large genomic implementation study
Pacyna, Joel E. , Breitkopf, Carmen Radecki , Jenkins, Sarah M. , Sutton, Erica J., Horrow, Caroline , Sharp, Richard R. , Sharp, Richard R , Kullo, Iftikhar J.

Mayo Clinic

Journal of Medical Genetics | December 22, 2018 | Volume: 56 | Issue: 5 | Pages: 317-324

10.1136/jmedgenet-2018-105577 | PMID 30580287 Get It

Purpose We assessed the decision-making of individuals pursuing genomic sequencing without a requirement for pretest genetic counselling. We sought to describe the extent to which individuals who decline genetic counselling reported decisional conflict or struggled to make a decision to pursue genomic testing. Methods We administered a 100-item survey to 3037 individuals who consented to the Return of Actionable Variants Empirical study, a genomic medicine implementation study supported by the National Institutes of Health (USA) eMERGE consortium. The primary outcomes of interest were self-reported decisional conflict about the decision to participate in the study and time required to reach a decision. Results We received 2895 completed surveys (response rate=95.3%), and of these respondents 97.8% completed the decisional conflict scale in its entirety. A majority of individuals (63%) had minimal or no decisional conflict about the pursuit of genomic sequencing and were able to reach a decision quickly (78%). Multivariable logistic regression analyses identified several characteristics associated with decisional conflict, including lower education, lower health literacy, lower self-efficacy in coping, lack of prior experience with genetic testing, not discussing study participation with a family member or friend, and being male. Conclusion As genomic sequencing is used more widely, genetic counselling resources may not be sufficient to meet demand. Our results challenge the notion that all individuals need genetic counselling in order to make an informed decision about genomic sequencing.
430: REDUCTION OF INAPPROPRIATE PROTON PUMP INHIBITOR USE IN A MIXED INTENSIVE CARE UNIT
Peacock, Sarah , Mourad, Hesham , Moss, John, Moss, John E.

Mayo Clinic

Critical Care Medicine | December 18, 2018 | Volume: 47 | Issue: 1 | Pages: 195-195

10.1097/01.ccm.0000551182.32145.bd Get It